SGP: Innovative lens delivers glaucoma therapy during cataract surgery, with launch targeted for 2029
A new intraocular lens with drug delivery aims to address glaucoma during cataract surgery, targeting a $13 billion market. Clinical trials show strong efficacy and safety, with regulatory and reimbursement pathways established and a product launch expected in 2029.Based on SpyGlass Pharma, Inc. [S…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.